Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study
Jean-Baptiste Demigné, Marie Heinisch, Julia Gilhodes, Shems Kettani, Domitille Dano, Christelle de la Fouchardière · 2026
Read Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study by Jean-Baptiste Demigné, Marie Heinisch, Julia Gilhodes, Shems Kettani, Domitille Dano, Christelle de la Fouchardière (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13546603.txt.
Description
Jean-Baptiste Demigné and co-authors checked in 2026 how reliably HER2 status, a treatment-guiding marker in stomach and junction cancers, survives the trip from biopsy to surgery. Their single-center review covered 57 patients with localized disease who had curative surgery between 2017 and 2021, most after pre-surgery chemotherapy. Biopsy and surgical samples were tested with the same staining rules.
Agreement between the two samples was high, near 88 percent. Still, among twelve tumors that started HER2-positive, five lost that status by surgery, and half of the treated positive cases showed the loss. Taking more biopsy fragments did not reduce the mismatch. The authors suggest rechecking HER2 on the surgical specimen after pre-surgery treatment.
Catalog record
| CREATOR | Jean-Baptiste Demigné, Marie Heinisch, Julia Gilhodes, Shems Kettani, Domitille Dano, Christelle de la Fouchardière |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32329 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |